Suppr超能文献

犬附肢骨肉瘤卡铂治疗期间体重变化的评估

Evaluation of Weight Change During Carboplatin Therapy in Dogs With Appendicular Osteosarcoma.

作者信息

Story A L, Boston S E, Kilkenny J J, Singh A, Woods J P, Culp W T N, Skorupski K A, Lu X

机构信息

College of Veterinary Medicine, University of Florida, Gainesville, FL.

Ontario Veterinary College, University of Guelph, Guelph, ON, Canada.

出版信息

J Vet Intern Med. 2017 Jul;31(4):1159-1162. doi: 10.1111/jvim.14724. Epub 2017 May 15.

Abstract

BACKGROUND

The prevalence of cancer cachexia in veterinary medicine has not been studied widely, and as of yet, no definitive diagnostic criteria effectively assess this syndrome in veterinary patients.

OBJECTIVES

(1) To determine the patterns of weight change in dogs with appendicular osteosarcoma treated with amputation and single-agent carboplatin during the course of adjuvant chemotherapy; and (2) to determine whether postoperative weight change is a negative prognostic indicator for survival time in dogs with osteosarcoma.

ANIMALS

Eighty-eight dogs diagnosed with appendicular osteosarcoma. Animals were accrued from 3 veterinary teaching hospitals.

METHODS

Retrospective, multi-institutional study. Dogs diagnosed with appendicular osteosarcoma and treated with limb amputation followed by a minimum of 4 doses of single-agent carboplatin were included. Data analyzed in each patient included signalment, tumor site, preoperative serum alkaline phosphatase activity (ALP), and body weight (kg) at each carboplatin treatment.

RESULTS

A slight increase in weight occurred over the course of chemotherapy, but this change was not statistically significant. Weight change did not have a significant effect on survival. Institution, patient sex, and serum ALP activity did not have a significant effect on survival.

CONCLUSIONS AND CLINICAL IMPORTANCE

Weight change was not a prognostic factor in these dogs, and weight loss alone may not be a suitable method of determining cancer cachexia in dogs with appendicular osteosarcoma.

摘要

背景

兽医学中癌症恶病质的患病率尚未得到广泛研究,截至目前,尚无明确的诊断标准能有效评估兽医患者的这一综合征。

目的

(1)确定接受截肢和单药卡铂辅助化疗的犬肢端骨肉瘤患者在化疗过程中的体重变化模式;(2)确定术后体重变化是否是骨肉瘤犬生存时间的不良预后指标。

动物

88只被诊断为肢端骨肉瘤的犬。动物来自3家兽医教学医院。

方法

回顾性多机构研究。纳入诊断为肢端骨肉瘤并接受肢体截肢,随后至少接受4剂单药卡铂治疗的犬。分析的每位患者的数据包括特征、肿瘤部位、术前血清碱性磷酸酶活性(ALP)以及每次卡铂治疗时的体重(kg)。

结果

化疗过程中体重略有增加,但这种变化无统计学意义。体重变化对生存无显著影响。机构、患者性别和血清ALP活性对生存无显著影响。

结论及临床意义

体重变化不是这些犬的预后因素,仅体重减轻可能不是确定肢端骨肉瘤犬癌症恶病质的合适方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d24/5508317/2de3a777f899/JVIM-31-1159-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验